Las Vegas, NV -- (SBWIRE) -- 10/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: ChemoCentryx Inc (NASDAQ:CCXI), Agilent Technologies Inc. (NYSE:,A), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Aastrom Biosciences Inc (NASDAQ:ASTM)
ChemoCentryx Inc (NASDAQ:CCXI) managed to keep its fall at -1.10% on above-normal volume of 1.89M shares. The stock settled at $5.41 after floating in a range of $5.40 to $5.51. Its latest price has reached market capitalization of $231.74 million. Its 52-week range has been $5.80 to $14.96. ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.
Has CCXI Found The Bottom and Ready To Move Up? Find Out Here
Agilent Technologies Inc. (NYSE:A) traded up on a volume of 1.87 million, lower than its standard daily volume. Shares have gained 1.41% to $51.78. Over the last twelve months, the stock has gained 34.67% and faced a worst price of $35.38. Agilent Technologies, Inc. (Agilent) is a measurement company providing bio-analytical and electronic measurement solutions to the communications, electronics.
For How Long A’s Gloss will Attract Investors? Find out via this report
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) settled 1.88% higher at $28.77 on below -normal volume of 1.87M shares during the last trading day. The stock has its 12-month high at $29.73 and 52-week low price was $1.80. It traded in a range of $28.58 to $29.16 during the last trading day. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.
Why Should Investors Buy ACAD After the Recent Fall? Just Go Here and Find Out
In the last trading session, Aastrom Biosciences Inc (NASDAQ:ASTM) was down on high volume, trading at a volume of 1.81M versus its average daily volume of 1.26 million shares. At $0.274, the stock has attained market capitalization of 20.73 million. Aastrom Biosciences, Inc. (Aastrom) is a development-stage company. The Company is a regenerative medicine company focused on the development of cell therapies to repair or regenerate damaged or diseased tissues.
Why Should Investors Buy ASTM After the Recent Fall? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)